2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Vaccines, Bispecific Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, ALL, B Cell Lymphoma, T Cell Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5056 Predictors of central nervous system relapse in adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the contemporary era

Georgio Medawar, MD, Hannah Goulart, MD2, Nitin Jain, MD3, Fadi G. Haddad, MD4, Alex Bataller, MD, PhD5, Jayastu Senapati, MBBS, MD, DM6, Dany Nassar, MD7, Rebecca Garris8, Guillermo Garcia-Manero, MD9, Nicholas Short, MD10, Hagop Kantarjian, MD11, Elias Jabbour, MD12
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background

Central nervous system (CNS) relapse remains a major cause of treatment failure in adult acute lymphoblastic leukemia (ALL) despite intrathecal (IT) prophylaxis and intensified systemic therapy. Previously identified CNS risk factors include a high white blood cell (WBC) count, elevated LDH, adverse cytogenetics, and prior CNS disease. However, data specific to adult Philadelphia chromosome (Ph)-negative B-ALL treated with hyper-CVAD-based and immunotherapy-containing regimens including blinatumomab (Blina) and inotuzumab ozogamicin (InO) are limited. We characterized predictors of CNS relapse in a large single-institution cohort.

Methods

We retrospectively analyzed adults with newly diagnosed Ph-negative B-ALL treated at our institution from 11/2002 to 06/2024. Baseline demographics, presenting WBC, marrow blast percentage, LDH, CRLF2 rearrangement status, cytogenetic risk (high- defined as KMT2A rearranged, complex karyotype, low hypodiploidy, or near-triploidy), CNS-involvement, frontline treatments, were compared across patients with no relapse, relapse, non-CNS relapse, CNS-involved relapse, and CNS-only relapse. Multivariable (MVA) fine-gray competing risks regression was used to identify independent predictors of CNS relapse.

Results

We identified 470 frontline patients with Ph-negative B-ALL, of whom 321 (68%) remained in remission and 149 (32%) relapsed. Of these, 118 (79%) had non-CNS relapse, 31 (21%) had CNS involvement at relapse, including 14 (45%) with CNS-only relapse.

Comparing non-relapsed pts to relapsed pts, respectively: median (med) age was 43 years (yrs) vs 38 yrs (p=.004), med baseline peripheral blood (PB) WBC was 4.2x109/L vs 12.8 x109/L (p<.0001), med LDH 876 vs 1,198 (p=.0001), CRLF2 rearrangement was 24 (7%) vs 21 (14%) (p=.028), med bone marrow (BM) blast percentage (%) 84 vs 88% (p=0.004). Less intensive (LIC) frontline regimens (i.e. miniHCVD + InO/Blina) were used in 17% vs 9% (p=.02). Overall, Ino and/or Blina were added to backbone chemotherapy in 39% vs 13% (p<.0001). Adverse cytogenetics and CNS involvement at diagnosis were not significantly different.

We then compared non-CNS relapse to CNS-involved relapse, respectively: med age was 39 yrs (range 25-62) vs 24 yrs (range 16-70) (p=.0021); Baseline WBC and LDH, BM blast %, CRLF2 rearrangements, adverse cytogenetics, and CNS involvement at diagnosis were not significantly different. Med number of IT prophylaxis doses was 8 (range 2-17) vs 8 (range 4-19) (p=.031). Med time from CR to relapse was 17 months (m) (range 0.6-112 m) vs 20 m (range 3-48 m) (p=.78). Frontline LIC regimens were used in 8% vs 10% (p=.71). Overall, InO and/or Blina were added to backbone chemotherapy in 13% vs 16% (p=.56). At relapse, extramedullary involvement other than CNS occurred in 5% vs 6% (p=.67).

Among the 14 patients with CNS-only relapse, med age was 21 yrs (range 16-70). Adverse cytogenetics were present in 7% and CRLF2 rearrangements in 29%. Med number of IT prophylaxis doses was 10 (range 4-15), and med time to relapse was 18 m (range 7-37). Med baseline WBC was 28 (range 2-156) x109/L, med PB blast was 66% (range 0-86), med BM blast was 91% (range 17-97), and med LDH was 2,031 U/L (range 732-8,443). Frontline IC (hyper-CVAD and augmented BFM) +/- InO/Blina were used in 71% of cases.

The median OS from the time of CNS relapse was 32.5 m (95% CI 6.6-119.9); this did not differ between pts with isolated CNS relapse vs combined CNS/systemic relapse.

On Fine-gray competing risks regression multivariable analysis to assess the risk of CNS relapse amongst Ph-negative ALL patients with baseline data, younger age (HR 0.61 per 10-year increase, 95% CI 0.43–0.86, p=.005) and higher baseline LDH (HR 1.32 per doubling, 95% CI 1.10–1.57, p=.002) were independently associated with increased risk of CNS relapse. Presenting WBC >70 (HR 0.56, p=.30), baseline CNS involvement (HR 1.05, p=.93), high-risk cytogenetics (HR 1.94, p=0.13), and treatment backbone (HR 4.70, p=.089) were not associated with increased risk.

Conclusions

CNS relapse occurred in one-fifth of relapses in adults with Ph-negative B-ALL and was associated with younger age and higher LDH at diagnosis. Notably, less intensive regimens with concurrent blina/InO based regimens and baseline WBC count were not independently associated with an increased risk of relapse. These findings may help identify patients at increased risk of CNS relapse at initial diagnosis and warrants further evaluation.

Georgio Medawar, MD: No relevant conflicts of interest to declare.